(156 days)
Not Found
No
The document describes a software update for a linear accelerator system used in radiation therapy. While it mentions image processing and data processing, there is no explicit mention of AI, ML, deep learning, or any related concepts in the intended use, device description, or performance studies. The focus is on standard software functionalities for patient setup, treatment delivery, and data management.
No
The device is described as a component of a linear accelerator system, which delivers radiation for therapeutic treatment. However, the device itself, the syngo® RT Therapist Workspace, is a software application that supports patient selection/setup, patient position, treatment delivery/verification, and treatment recording. It does not directly deliver therapy, but rather manages and facilitates the therapeutic process carried out by the linear accelerator. Therefore, it is not a therapeutic device itself.
No
This device, a linear accelerator system and its associated software (syngo® RT Therapist Workspace), is explicitly stated to be for "therapeutic treatment of cancer" by delivering radiation. While it uses imaging for patient setup and verification, its primary function is treatment delivery, not diagnosis.
No
The device is described as a component of a linear accelerator system, which is a hardware device. While the submission focuses on a software update, the software's function is to control and support the operation of the hardware.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is clearly stated as delivering radiation for the therapeutic treatment of cancer. This is a therapeutic device, not a diagnostic one.
- Device Description: The description focuses on the software's role in supporting patient setup, position, treatment delivery, verification, and recording within the context of radiation therapy. It does not mention any analysis of biological samples or substances.
- Lack of IVD Characteristics: An IVD device is used to examine specimens derived from the human body to provide information for diagnosis, monitoring, or screening. This device does not perform such functions.
The mentions of "data processing, image reformatting, display and printing" and "image-oriented software tools" relate to the processing and display of medical images (likely from imaging modalities used for treatment planning and verification), which is common for therapeutic devices but does not make it an IVD.
N/A
Intended Use / Indications for Use
The intended use of the SIEMENS branded ARTISTE™ , ONCOR™ and PRIMUS™ family of linear accelerator systems is to deliver X-Ray photon and electron radiation for the therapeutic treatment of cancer.
The linear accelerator systems are high-dose rate medical linear accelerators optimized for 3D conformal radiation therapy, intensity-modulated radiation therapy (IMRT), modulated arc therapy (mARC) and precision stereotactic radiation therapy for lesions, turnors and conditions anywhere in the head and body where radiation therapy is indicated.
The syngo® RT Therapist workspace is a component of the linear accelerator system and is based on the syngo® architecture. The syngo® RT Therapist workspace contains software applications to support patient selection/setup, patient positioning verification, treatment delivery/verification, and treatment recording.
The syngo® RT Therapist Workspace v4.3.1 can be interfaced with third party devices conforming to the DICOM Standard.
Product codes
IYE
Device Description
The syngo® RT Therapist Workspace v4.3.1 release is intended to update customers with the currently released syngo® RT Therapist Workspace software with version v4.3 for ARTISTE, ONCOR & PRIMUS Linear Accelerator systems. The technological characteristics and the fundamental technology of the syngo® RT Therapist Workspace v4.3.1 remain unchanged from the currently cleared products.
The syngo® RT Therapist software utilizes the proprietary syngo® software architecture design that provides a method of delivering customized software applications based on the modality as clinically supporting packages. SIEMENS utilizes, as part of the Oncology clinical focus package, multiple syngo® software applications for patient set-up and position verification, treatment localization, treatment verification, portal imaging as well as data processing, image reformatting, display and printing. The currently cleared syngo® based software products also includes an array of image-oriented software tools, support for DICOM connectivity, Siemens Remote Service [SRS], and virus protection features.
This update is intended to be backwards compatible to upgrade the currently cleared ONCOR and PRIMUS family of medical linear accelerators and their Control Consoles (v9.2+ & v11.0, v12), the COHERENCE™ RT Therapist (v2.3) workspace (K123812). Additionally, the ARTISTE Solution with the syngo® RTT v4.1x and v4.2x (K103606) can also be upgraded. These previous versions can be migrated to the current release (syngo® RTT. v4.3) and Control Console 13.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
anywhere in the head and body
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Bench testing in the form of Unit, Integration and System Integration testing was performed to evaluate the performance and functionality of the software update v4.3.1 for the RT Therapist and regression testing the Control Console version 13.
All testable requirements in the System Requirements Specifications (SRS) and Component Requirements (CRS) for the Sys_VC10C project, and additionally the specific requirements for the implementation of the third party OIS have been successfully verified and traced in accordance with the Siemens product development (lifecycle) process (PDP).
The software verification and regression testing has been performed successfully to meet their previously determined acceptance criteria as stated in the Test Concept.
Validation of the syngo® RT Therapist Workspace v4.3.1, implementation of the optional third party OIS and regression testing with Control Consoles 13 has been performed at the System test level on production prototype devices by appropriately trained and knowledgeable test personnel. System level validation and regression testing has been performed successfully, demonstrating that the software meets the acceptance criteria as noted in the system test plans.
The syngo® RT Therapist Workspace v4.3.1 and the Control Console 13 supporting the third party OIS and V&R implementation have been tested to meet the requirements for conformity (where applicable) to multiple industry standards.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.5050 Medical charged-particle radiation therapy system.
(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
K132935
Page 1 of 5
FEB 2 1 2014
Section 5
510(k) Summary
| Date Prepared: | September 12, 2013 | |||
|---|---|---|---|---|
| Submitter: | Siemens Medical Solutions USA, Inc. | |||
| Radiation Oncology | ||||
| 757A Arnold Drive | ||||
| Martinez, CA 94553 | ||||
| Contact: | Christine Dunbar | |||
| Senior Manager, Regulatory Affairs | ||||
| Phone: | ||||
| Fax: | ||||
| Email: | (925)293-5442 | |||
| (925)602-8008 | ||||
| christine dunbar@siemens.com | ||||
| Proprietary Name: | syngo® RT Therapist Workspace, v4.3.1 | |||
| And the optional 30 party OIS Connectivity System | ||||
| Common Name: | Accessory To; Medical Charged-Particle Radiation Therapy System | |||
| Classification: | 892.5050 | |||
| Product Code: | IYE | |||
Substantial Equivalence Claimed To:
| Product | 510(k)
Clearance / Date | Claim of Equivalence for: |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| COHERENCE™ RT Therapist
Connect update to Sys_32A
(RTTC v2.3) with Control
Console 9.2.18 and 11.0.212
supporting 3rd party OIS, V&R
called ARIA and Varian
Treatment8 and third party TPS
and PACs systems | K123812 /
March 01, 2013 | Syngo® RT Therapist with software
version 4.3.1, with Control Console v13,
an update to Sys_VC10C supporting 3rd
party OIS, V&R called ARIA and Varian
Treatment9 and third party TPS and
PACs systems |
| ARTISTE™ Solution with SYS-
VC10A for the syngo® RT
Therapist (RTT v4.3, CC 13)
supporting 3rd party OIS, V&R | K121295 / June
12, 2012 | Syngo® RT Therapist with software
version 4.3.1, with Control Console v13,
an update to Sys_VC10C supporting 3rd
party OIS, V&R called ARIA and Varian |
8 ARIA OIS and Varian Treatment V&R systems are manufactured by Varian Medical Systems. ARIA OIS and Varian Treatment Vart Systems are manufactured by Varian Medical Systems.
9 ARIA OIS and Varian Treatment V&R systems are manufactured by Varian Medical Systems.
510(k) for SIEMENS syngo® RT Therapist v4.3.x and 3rd Party OlS Section/ Page - 5/1
1
| called MOSAIQ and Sequencer
V&R10 and third party TPS and
PACs systems. | | Treatment11 and third party TPS and
PACs systems |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| syngo® RT Therapist Connect
(RTT v4.2, CC 12)
(ARTISTE, ONCOR and
PRIMUS Linacs) supporting 3rd
party OIS, V&R called MOSAIQ
and Sequencer V&R12 and third
party TPS and PACs systems | K103606 /
April15, 2011 | syngo® RT Therapist with software
version 4.3.1, with Control Console v13,
an update to Sys_VC10C supporting 3rd
party OIS, V&R called ARIA and Varian
Treatment13 and third party TPS and
PACs systems. |
The update to the syngo® RT Therapist Workspace, v4.3.1 as described in this premarket notification has the same intended use and fundamental scientific technical characteristics as the predicate devices listed above.
Description Summary
syngo® RT Therapist Workspace, v4.3.1
Technological Characteristics:
The syngo® RT Therapist Workspace v4.3.1 release is intended to update customers with the
currently released syngo® RT Therapist Workspace software with version v4.3 for ARTISTE, ONCOR & PRIMUS Linear Accelerator systems. The technological characteristics and the fundamental technology of the syngo® RT Therapist Workspace v4.3.1 remain unchanged from the currently cleared products.
The syngo® Software Architecture:
The syngo® RT Therapist software utilizes the proprietary syngo® software architecture design that provides a method of delivering customized software applications based on the modality as clinically supporting packages. SIEMENS utilizes, as part of the Oncology clinical focus package, multiple syngo® software applications for patient set-up and position verification, treatment localization, treatment verification, portal imaging as well as data processing, image reformatting, display and printing. The currently cleared syngo® based software products also includes an array of image-oriented software tools, support for DICOM connectivity, Siemens Remote Service [SRS], and virus protection features. Note: syngo® is both a proprietary software architecture and a market brand.
This update is intended to be backwards compatible to upgrade the currently cleared ONCOR and PRIMUS family of medical linear accelerators and their Control Consoles (v9.2+ & v11.0, v12), the COHERENCE™ RT Therapist (v2.3) workspace (K123812). Additionally, the ARTISTE
11 ARIA OIS and Varian Treatment V&R systems are manufactured by Varian Medical Systems.
12 MOSAIQ OIS and Sequencer V&R systems are manufactured by IMPAC Medical / Elekta AB.
13 ARIA OIS and Varian Treatment V&R systems are manufactured by Varian Medical Systems.
510(k) for SIEMENS syngo® RT Therapist v4.3.x and 3d Party OlS Section/ Page - 5/2
10 MOSAIQ OIS and Sequencer V&R systems are manufactured by IMPAC Medical / Elekta AB.
2
Solution with the syngo® RTT v4.1x and v4.2x (K103606) can also be upgraded. These previous versions can be migrated to the current release (syngo® RTT. v4.3) and Control Console 13.
General Safety and Effectiveness:
The device labeling contains instructions for use and any necessary cautions and warnings, to provide for safe and effective use of the device.
Risk management is ensured via a risk analysis, which is used to identify potential hazards and mitigations. These potential hazards are controlled by software means, user instructions, verification of requirements and validation of the clinical workflow to ensure that the product meets its intended uses. To minimize electrical, mechanical and radiation hazards, SIEMENS adheres to recognized and established industry practice and relevant international standards.
Refer to Section 21 for the Risk Management documentation.
Intended Use:
The intended use of the SIEMENS branded ARTISTE™ , ONCOR™ and PRIMUS™ family of linear accelerator systems is to deliver X-Ray photon and electron radiation for the therapeutic treatment of cancer.
The linear accelerator systems are high-dose rate medical linear accelerators optimized for 3D conformal radiation therapy, intensity-modulated radiation therapy (IMRT), modulated arc therapy (mARC) and precision stereotactic radiation therapy for lesions, turnors and conditions anywhere in the head and body where radiation therapy is indicated.
The syngo® RT Therapist workspace is a component of the linear accelerator system and is based on the syngo® architecture. The syngo® RT Therapist workspace contains software applications to support patient selection/setup, patient positioning verification, treatment delivery/verification, and treatment recording.
The syngo® RT Therapist Workspace v4.3.1 can be interfaced with third party devices conforming to the DICOM Standard.
Substantial Equivalence:
The Substantial Equivalence comparison chart demonstrates the comparison of the technological characteristics of the synqo® RT Therapist Workspace update to the currently cleared predicate devices.
The syngo® RT Therapist Workspace v4.3.1 (project Sys_VC10C) does not change the intended use of the original ARTISTE™ Solution with the syngo® RT Therapist Workspace v4.3 (project Svs VC10A) or the previously cleared ONCOR™ or PRIMUS™ Siemens branded Linear Accelerator Systems.
Bench Testing:
3
Bench testing in the form of Unit, Integration and System Integration testing was performed to evaluate the performance and functionality of the software update v4.3.1 for the RT Therapist and regression testing the Control Console version 13.
All testable requirements in the System Requirements Specifications (SRS) and Component Requirements (CRS) for the Sys_VC10C project, and additionally the specific requirements for the implementation of the third party OIS have been successfully verified and traced in accordance with the Siemens product development (lifecycle) process (PDP).
The software verification and regression testing has been performed successfully to meet their previously determined acceptance criteria as stated in the Test Concept.
Non-Clinical Test Results:
Validation of the syngo® RT Therapist Workspace v4.3.1, implementation of the optional third party OIS and regression testing with Control Consoles 13 has been performed at the System test level on production prototype devices by appropriately trained and knowledgeable test personnel. System level validation and regression testing has been performed successfully, demonstrating that the software meets the acceptance criteria as noted in the system test plans.
Testing to Consensus Standards:
The syngo® RT Therapist Workspace v4.3.1 and the Control Console 13 supporting the third party OIS and V&R implementation have been tested to meet the requirements for conformity (where applicable) to multiple industry standards.
Refer to Sections 9 and 17 for this content.
Substantial Equivalence to Predicates:
The verification testing to the System requirements for the syngo® RT Therapist workspace, validation of the intended use, and the regression testing to the existing syngo® RT Therapist software and Control Console functional requirements, is intended to support the claim of substantial equivalence to the following predicates:
- The COHERENCE™ RT Therapist Connect v2.3 with Control Consoles 9.2.18 and . 11.0.212 supporting 3d party OIS & V&R (ARIA and Varian Treatment™ System) and third party TPS and PACs systems (K123812).
- The ARTISTE™ Solution with SYS-VC10A for the syngo® RT Therapist (RTT v4.3, . CC 13) supporting 310 party OIS & V&R (MOSAIQ and Sequencer V&R15) and third party TPS and PACs systems. (K121295).
- The syngo® RT Therapist Connect (RTT v4.2, CC 12) (ARTISTE, ONCOR and . PRIMUS Linacs) supporting 30 party OIS & V&R (MOSAIQ and Sequencer V&R10) and third party TPS and PACs systems (K103606).
14 ARIA OIS and Varian Treatment V&R systems are manufactured by Varian Medical Systems.
15 MOSAIQ OIS and Sequencer V&R systems are manufactured by IMPAC Medical / Elekta AB.
16 MOSAIQ OIS and Sequencer V&R systems are manufactured by IMPAC Medical / Elekta AB.
510(k) for SIEMENS syngo® RT Therapist v4.3.x and 3rd Party OIS Section/ Page - 5/4
4
K132935
page 5 of 5
Summary:
In summary, it is SIEMENS' opinion that the syngo® RT Therapist Workspace update to v4.3.1 including the optional 3" party OIS Connectivity system (ARIA OIS), does not introduce any new
potential safety risks and is substantially equivalent to, and performs as well devices.
....
5
Image /page/5/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is a stylized symbol that resembles a human figure embracing a three-barred cross, which is the symbol of the Public Health Service.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
February 21, 2014
SIEMENS MEDICAL SOLUTIONS USA, INC. % CHRISTINE DUNBAR SENIOR MANAGER, REGULATORY AFFAIRS 757A ARNOLD DRIVE MARTINEZ CA 94553
Re: K132935
Trade/Device Name: syngo® RT Therapist Workspace, v4.3.1 & optional 3d party OIS Connectivity System Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: IYE Dated: October 4, 2013 Received: October 7, 2013
Dear Ms. Dunbar:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
6
Page 2-Ms. Dunbar
and the country of the states a
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely vours.
Jaming Jr. Marge
Janine M. Morris Director, Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
7
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
ndications for Use
510(k) Number (if known) K132935
Device Name
syngo RT Therapist Workspace, v4.3.1
Indications for Use (Describe)
The intended use of the SIEMENS branded ARTISTE™, ONCOR™ and PRIMUS™ family of linear accelerator systems is to deliver X-ray photon and electron radiation for the therapeutic treatment of cancer.
The linear accelerator systems are high-dose and high-dose rate medical linear accelerators optimized for 3D conformal radiation therapy, intensity-modulated radiation therapy (IMRT), modulated arc therapy (mARC) and precision stereotactic radiation therapy for lesions, turnors and conditions anywhere in the head and body where radiation therapy is indicated.
The syngo® RT Therapist workspace is a component of the linear accelerator system and is based on the syngo@ architecture. The syngo@ RT Therapist workspace contains software applications to support patient selection/setup, patient position, treatment delivery/verification. and treatment recording.
The syngo® RT Therapist Workspace v4.3.1, can be interfaced with third party devices conforming to the DICOM Standard.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement on last page.
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
Michael D. O'HaraFORM FDA 3881 (1/14)
PSC Publishing Sen sees (30) ) 441-47 an E
8
This section applies only to requirements of the Paperwork Reduction Act of 1995.
... . . . . . . . . "DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."